Zydus Lifesciences Limited (ZYDUSLIFE) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated August 06, 2026 3 min read

Zydus Lifesciences is navigating a pivotal transition as it balances high-growth innovation in specialty pharma with the competitive headwinds facing its legacy US generic portfolio. Investors will be watching for the impact of recent acquisitions like Assertio Holdings and the commercial ramp-up costs for Saroglitazar on the company's margin trajectory this quarter.

Quick Details

Results date	August 11, 2026
Quarter	Q1 FY 2026-2027
Previous quarter revenue	Rs. 7,587.0 Cr
Previous quarter PAT	Rs. 1,272.5 Cr
Previous quarter EBITDA margin	33.7%
Net debt (latest quarter)	Rs. 4,305 Cr
Market cap	Rs. 111,352.03 Cr
CMP	Rs. 1106.25

Zydus Lifesciences Limited Q1 Results Date and Time

The board meeting is scheduled for August 11, 2026, to approve the unaudited Q1 FY27 financial results.

The company previously recommended a final dividend of Rs. 1/share for FY26, payable by August 14, 2026.

What to expect from Zydus Lifesciences Limited's Q1 FY27 results

Management's FY27 outlook targets consolidated revenue growth in the high-teens and EBITDA margins exceeding 24%, testing the company's ability to offset generic price erosion with specialty launches. India branded formulations are expected to maintain momentum, with management aiming to outperform the Indian Pharma Market by 200-400 bps, supported by a chronic portfolio that reached 45.3% share in Q3 FY26. US revenue faces a challenging quarter as the Mirabegron patent trial and subsequent competition impact a segment that previously contributed $323 Mn in Q4 FY26. The upcoming call will likely focus on the sequential EBITDA margin compression from Q4's 33.7% peak, driven by the normalization of a Rs. 644.9 Cr forex gain and the integration of the Assertio Holdings acquisition completed on June 16, 2026.

Key Things To Watch

Performance vs Guidance Tracking: Tracking Q1 results against management's annual targets for FY27.

Consolidated revenue growth — High-teens — FY27 target
North America growth — Single-digit — FY27 target
EBITDA margin — In excess of 24% — FY27 target
R&D spend — ~8% of revenue — FY27 target

Strategic Initiatives and M&A: Integration and regulatory milestones for key growth platforms.

Assertio Holdings integration status following June 16, 2026 completion
Saroglitazar NDA USFDA acceptance and commercial infrastructure build-up
Sterling Biotech API acquisition closing status extended to September 30, 2026
Semaglutide international expansion progress in Canada and Brazil

Risks and Headwinds to Monitor: Operational and legal factors impacting quarterly performance.

Mirabegron litigation status and impact on US revenue exclusivity
Stamp duty demand of Rs. 108.54 Mn regarding Sterling Biotech asset transfer
US generic pricing pressure trends in Q1 compared to single-digit erosion levels

Frequently Asked Questions

What is the status of Zydus Lifesciences' EBITDA margin guidance?

Management has guided for FY27 EBITDA margins in excess of 24%. This target incorporates the impact of competitive headwinds, including Mirabegron competition and incremental commercial expenses for Saroglitazar.

How did the Assertio Holdings acquisition impact the company?

Zydus completed the acquisition of US-based Assertio Holdings for USD 166.33 Mn on June 16, 2026. The company is now a wholly owned subsidiary, with management focused on realizing synergies in oncology supportive care.

Is Zydus Lifesciences' India branded business growing?

Yes, India branded formulations have consistently outperformed the market, with 14% YoY growth reported in Q4 FY26. Management targets outperforming the broader Indian Pharma Market by 200-400 bps for FY27.